WO2004033710A3 - Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol - Google Patents

Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol Download PDF

Info

Publication number
WO2004033710A3
WO2004033710A3 PCT/US2003/032361 US0332361W WO2004033710A3 WO 2004033710 A3 WO2004033710 A3 WO 2004033710A3 US 0332361 W US0332361 W US 0332361W WO 2004033710 A3 WO2004033710 A3 WO 2004033710A3
Authority
WO
WIPO (PCT)
Prior art keywords
itgb3
haplotypes
hdl cholesterol
methods
dose effects
Prior art date
Application number
PCT/US2003/032361
Other languages
French (fr)
Other versions
WO2004033710A2 (en
Inventor
Steven C Bentivegna
Karen M Bieglecki
Carlos D Brain
Bradley J Dain
Gina-Marie Cappola
Richard S Judson
Michael Lachowicz
Helen H Lee
Lynne Litvyn
Chad Messer
Nathan Petersen
Carol R Reed
Eileen M Rounds
David P Russo
Andreas K Windemuth
Original Assignee
Genaissance Pharmaceuticals
Steven C Bentivegna
Karen M Bieglecki
Carlos D Brain
Bradley J Dain
Gina-Marie Cappola
Richard S Judson
Michael Lachowicz
Helen H Lee
Lynne Litvyn
Chad Messer
Nathan Petersen
Carol R Reed
Eileen M Rounds
David P Russo
Andreas K Windemuth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaissance Pharmaceuticals, Steven C Bentivegna, Karen M Bieglecki, Carlos D Brain, Bradley J Dain, Gina-Marie Cappola, Richard S Judson, Michael Lachowicz, Helen H Lee, Lynne Litvyn, Chad Messer, Nathan Petersen, Carol R Reed, Eileen M Rounds, David P Russo, Andreas K Windemuth filed Critical Genaissance Pharmaceuticals
Priority to AU2003284111A priority Critical patent/AU2003284111A1/en
Publication of WO2004033710A2 publication Critical patent/WO2004033710A2/en
Publication of WO2004033710A3 publication Critical patent/WO2004033710A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Haplotypes of the ITGB3 gene that are associated with atorvastatin dose effects on changes in HDL cholesterol are disclosed. Compositions and methods for detecting and using these ITGB3 haplotypes in a variety of clinical applications, as well as in pharmaceutical research and development contexts, are disclosed. Such applications include articles of manufacture comprising a statin composition approved for treating patients having one of these ITGB3 haplotypes, methods and kits for predicting the response of an individual to atorvastatin treatment based on their haplotype profile, and methods for treating individuals with hyperlipidemia based on their haplotype profile.
PCT/US2003/032361 2002-10-09 2003-10-09 Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol WO2004033710A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003284111A AU2003284111A1 (en) 2002-10-09 2003-10-09 Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41774302P 2002-10-09 2002-10-09
US60/417,743 2002-10-09

Publications (2)

Publication Number Publication Date
WO2004033710A2 WO2004033710A2 (en) 2004-04-22
WO2004033710A3 true WO2004033710A3 (en) 2004-11-18

Family

ID=32094078

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/032361 WO2004033710A2 (en) 2002-10-09 2003-10-09 Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol

Country Status (2)

Country Link
AU (1) AU2003284111A1 (en)
WO (1) WO2004033710A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362248B2 (en) 2005-01-10 2013-01-29 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US8410119B2 (en) 2003-07-14 2013-04-02 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013008100A2 (en) 2010-09-22 2016-08-09 Arena Pharm Inc "gpr19 receptor modulators and the treatment of disorders related thereto."
CN116850181A (en) 2015-01-06 2023-10-10 艾尼纳制药公司 Treatment and S1P 1 Methods of receptor-related disorders
MX2017016530A (en) 2015-06-22 2018-03-12 Arena Pharm Inc Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluo romethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)a cetic acid(compound1) for use in sipi receptor-associated disorders.
CN110520124A (en) 2017-02-16 2019-11-29 艾尼纳制药公司 For treating the Compounds and methods for of primary biliary cholangitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8410119B2 (en) 2003-07-14 2013-04-02 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US8362248B2 (en) 2005-01-10 2013-01-29 Arena Pharmaceuticals, Inc. Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto

Also Published As

Publication number Publication date
WO2004033710A2 (en) 2004-04-22
AU2003284111A8 (en) 2004-05-04
AU2003284111A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
WO2004006858A3 (en) Compounds, compositions, and methods employing same
PT1679058E (en) Pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases
NO20050497L (en) Use of CETP inhibitors and optionally HMG COA reducible inhibitors and / or antihypertensive agents
WO2005033102A3 (en) Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2008151803A3 (en) New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
EP2281561A3 (en) Use of LCK inhibitors for treatment of immunologic diseases
WO2005072151A3 (en) Apoe genetic markers associated with age of onset of alzheimer's disease
WO2006020430A8 (en) Novel composition and methods for the treatment of immune related disease
WO2004033710A3 (en) Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
WO2003087325A3 (en) Methods and compositions for preventing and treating microbial infections
WO2005059105A3 (en) Cdk5 genetic markers associated with galantamine response
BRPI0409609A (en) reverse cholesterol transport mediators for the treatment of hypercholesterolemia
WO2005072152A3 (en) Apoc1 genetic markers associated with age of onset of alzheimer's disease
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2005108605A3 (en) Polymorphisms in abcb1 associated with a lack of clinical response to medicaments
WO2004003167A3 (en) Gucy1b2 genetic markers for ldl cholesterol response to statin therapy
WO2005072150A3 (en) Ldlr genetic markers associated with age of onset of alzheimer's disease
WO2003091698A3 (en) Cetp genetic markers for statin-specific changes in hdl cholesterol
WO2005042706A3 (en) Ephx2 genetic markers associated with galantamine response
EP1605963A4 (en) Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof
WO2008043570A8 (en) Interferon type i supporting compounds
WO2005037204A3 (en) Ntrk1 genetic markers associated with age of onset of alzheimer's disease
WO2005042762A3 (en) Lrpap1 genetic markers associated with galantamine response
WO2005021796A3 (en) Chrna2 genetic markers associated with galantamine response
PL1723234T3 (en) Vglut-specific dsrna compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP